Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes

Leukemia Research

Volumn 27, Issue 7, 2003, Pages 593-598

  Delforge, Michel ^a   Raets, Vicky ^a   Van Duppen, Victor ^a   Boogaerts, Marc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amifostine; Hematopoietic progenitor; HUMARA; Long term culture; Myelodysplasia; Short term culture

Indexed keywords

AMIFOSTINE; ANDROGEN RECEPTOR; CD34 ANTIGEN; GROWTH PROMOTOR;

ADULT; AGED; ARTICLE; BONE MARROW CULTURE; CELL GROWTH; CELL MATURATION; CELL STIMULATION; CLINICAL ARTICLE; CLONAL VARIATION; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MYELODYSPLASTIC SYNDROME; POLYMORPHIC LOCUS; PRIORITY JOURNAL; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANEMIA, REFRACTORY; ANTIGENS, CD34; CELL DIVISION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; FEMALE; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; RADIATION-PROTECTIVE AGENTS; RECEPTORS, ANDROGEN;

EID: 0037411217     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00099-1     Document Type: Article

References (30)

1. Heaney M.L., Golde D.W. Myelodysplasia. N. Engl. J. Med. 340:1999;1649.
2. Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 14:2000;2.
3. Boogaerts M., Verhoef G., Demuynck H. Treatment and prognostic factors in myelodysplastic syndromes. Baillieres Clin. Haematol. 9:1996;161.
4. De Witte T., Suciu S., Verhoef G., Labar B., Archimbaud E., Aul C.et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia following MDS. Blood. 98:2001;2326.
5. Delforge M., Demuynck H., Vandenberghe P., Verhoef G., Zachée P., Van Duppen V.et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 86:1995;3660.
6. Hellström-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M.et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomised phase II study and long-term follow-up of 71 patients. Blood. 92:1998;68.
7. Seng J.E., Peterson B.A. Low dose chemotherapy for myelodysplastic syndromes. Leuk. Res. 22:1998;481.
8. Raza A., Qawi H., Lisak L., Andric T., Dar S., Andrews C.et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 95:2000;1580.
9. Jonásová A., Neuwirtová R., Cermák J., Vozobulová V., Mociková K., Sisková M.et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 100:1998;304.
10. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profile. Br. J. Haematol. 102:1998;1314.
11. Silverman L.R., Holland J.F., Weinberg R.S., Alter B.P., Davis R.B., Ellison R.R.et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 7(1):1993;121.
12. Wijermans P., Lübbert M., Verhoef G., Bosly A., Ravoet C., Andre M.et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956.
13. Lübbert M., Wijermans P., Kunzman R., Verhoef G., Bosly A., Ravoet C.et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114:2001;349.
14. Vadhan-Raj S., Broxmeyer H., Spitzer G., LeMaistre A., Hultman S., Ventura G.et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 74:1989;1491.
15. Janssen J., Buschle M., Layton M., Drexler H., Lyons J., Van den Berghe H.et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 73:1989;248.
16. Ganser A., Janssen J., Ottman O., Seipelt G., Eder M., Becher R.et al. In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia. 5:1991;487.
17. Balzarotti M., Grisanti S., Granzow K., Saladini A., Sala A., Nozza A.et al. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin. Oncol. 26:1999;66.
18. Mehta M.P. Amifostine and combined-modality therapeutic approaches. Semin. Oncol. 26:1999;95.
19. List A.F., Heaton B., Glinsmann-Gibson B., Capizzi R.L. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 12:1998;1596.
20. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R.et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364.
21. Ribizzi I., Darnowski J.W., Goulette F.A., Sertoli M.R., Calabresi P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk. Res. 24:2000;519.
22. List A.F. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? Leuk. Res. 22:1998;S7.
23. Romano M.F., Lamberti A., Bisogni R., Garbi C., Pagnano A.M., Auletta P.et al. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood. 94(12):1999;4060.
24. List A.F. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin. Oncol. 26(7):1999;61.
25. Bowen D.T., Denzlinger C., Brugger W., Culligan D., Gelly K., Adlakha S.et al. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients. Br. J. Haematol. 103:1998;785.
26. Delforge M., Demuynck H., Verhoef G., Vandenberghe P., Zachée P., Maertens J.et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br. J. Haematol. 102:2000;486.
27. Anan K., Ito M., Misawa M., Ohe Y., Kohsaki M., Hara H. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the short tandem repeat on the human androgen-receptor (HUMARA) gene. Br. J. Haematol. 89:1995;838.
28. Aivado M., Rong A., Germing U., Gattermann N., Kobbe G., Rieth C.et al. Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. Br. J. Haematol. 110:2000;884.
29. Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T.et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 90:1997;1403.
30. Meier T., Issels R.D. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem. Pharmacol. 50:1995;489.